Everyday 20 children and adolescents in Europe die of cancer. We need to keep working together to improve early access to innovative drugs for children and adolescents with cancer
ECMC Paediatric Network
Childhood Cancer Parent Organization Mother & Child Health Care Institute of Serbia, Belgrade
Because all children have the right to grow up and lead a fulfilled and happy life. Because among children and teenagers with cancer we have a future researchers, future doctors, future artists, and above all, equal members of our society who need to have the same chance as the rest, and one day to contribute to the improvement and progress of the society, the improvement of the world and the preservation of the environment.
New drugs and less harsh treatments are desperately needed for children with cancer.
The ARC Foundation is committed to foster innovation in cancerology and accelerate the access to new and efficient therapies for all patients. During the last decade, significant improvements have already been made for adult patients, but children do not benefit from this trend so far. One of the ARC Foundation’s priority is to bring concrete improvements for children. To achieve this goal, it is urgent and mandatory to get significant changes within european regulations.
As parents of children with cancer we are aware that many efforts have been done, but the way to preserve children from cancer is still too long.
Adolescenti e cancro provides teenagers (13-19 years old) and young adults (20 – 30 years old) with peer to peer support and recreational activities such as on-line support, free days out and free holidays. We believe teens and young people need their peers support and our goal is to help them to connect with others in similar situations so they won’t face cancer alone.
The EURO EWING Consortium supports the Unite2Cure campaign to change European Paediatric Medicine Regulation as there is a need for better access to allow testing of new treatments for rare cancers like Ewing sarcoma, that mainly affect young people. Survival rates have not improved for 25 years and so new drugs and innovative trials are needed to make sure that more people are cured from this rare cancer
